Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $1.22M rose 17.4% year over year, ahead of the +10.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 95.1% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Stock-based compensation amounted to 12.0% of revenue in FY2025, down 1.8 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +17.4% holds above the trailing-twelve-month pace of +10.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 4.03M USD
- Year-over-year change
- +4.1%
- 4-year CAGR
- +21.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.03M | +4.1% |
| FY2024 | 2024-12-31 | 3.87M | -18.4% |
| FY2023 | 2023-12-31 | 4.75M | +18.2% |
| FY2022 | 2022-12-31 | 4.02M | +118.1% |
| FY2021 | 2021-12-31 | 1.84M | — |
Stock-Based Compensation vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 stock-based compensation of $4.21M is the 5th largest of the 9 companies compared; the peer median is $3.47M.
- Its year-over-year change of +10.0% is the 3rd highest of 9, against a peer median of -22.3%.
- Stock-based compensation amounts to 12.3% of revenue for RPID, versus a peer median of 10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.3B | +49501.8% | -33.1% | 44751.8% | |
| LTM Mar 2026 | $11.18M | +38.7% | -10.1% | 10.4% | |
| LTM Mar 2026 | $7.93M | -41.7% | +10.8% | 11.0% | |
| LTM Mar 2026 | $4.45M | -34.7% | +0.4% | 7810.5% | |
| LTM Mar 2026 | $4.21M | +10.0% | +0.1% | 12.3% | |
| LTM Mar 2026 | $2.49M | -6.7% | -22.0% | 4.3% | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| LTM Mar 2026 | $1.45M | -10.0% | +4.6% | — | |
| LTM Mar 2026 | $1.02M | -69.4% | -33.1% | 1.8% | |
| Peer median (excluding RPID) | $3.47M | -22.3% | -13.2% | 10.7% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.84M | 4.02M | 4.75M | 3.87M | 4.03M |
| Change in Working Capital | (8M) | (5.33M) | 555K | (4.77M) | 6.06M |
| Accounts Receivables | (17K) | (364K) | (163K) | (1.99M) | 4.39M |
| Inventory | (6.77M) | (5.84M) | 1.19M | (335K) | 1.47M |
| Accounts Payables | (524K) | 1.48M | (3.46M) | 562K | 1.6M |
| Other Working Capital | (691K) | (602K) | 2.98M | (3.01M) | (1.39M) |
| Other Non-Cash Items | 23.19M | 728K | (1.02M) | 271K | 2.71M |
| Operating Cash Flow | (54.96M) | (58.55M) | (45.08M) | (44.15M) | (31.06M) |
| Capital Expenditures | (3.22M) | (6.74M) | (1.85M) | (1.37M) | (850K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (25.09M) | (179.23M) | (62.49M) | (35.04M) | (27.08M) |
| Sales of Investments | 15M | 92.5M | 106.49M | 73.06M | 42.26M |
| Other Investing Activities | 20K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (13.29M) | (93.47M) | 42.15M | 36.66M | 14.33M |
| Debt Repayment | (26.17M) | (33K) | (37K) | (35K) | 19.09M |
| Common Stock Issued | 164.11M | 0 | 0 | 238K | 1.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (940K) | 726K | 186K | 0 | (419K) |
| Financing Cash Flow | 216.75M | 693K | 149K | 203K | 19.77M |
| Effect of Forex Changes | 0 | 0 | 0 | (81K) | 0 |
| Net Change in Cash | 148.49M | (151.32M) | (2.78M) | (7.37M) | 3.04M |
| Free Cash Flow | (58.18M) | (65.29M) | (46.93M) | (45.52M) | (31.91M) |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.